Lung Cancer Archives

Anti-Inflammatory Therapy With Canakinumab May Reduce Lung Cancer Rates

Anti-Inflammatory Therapy With Canakinumab May Reduce Lung Cancer Rates

Patients with lung cancer and atherosclerosis diagnosis may benefit from anti-inflammatory therapy with canakinumab.

Quality of Life Benefits of Yoga in Non-Small Cell Lung Cancer

Quality of Life Benefits of Yoga in Non-Small Cell Lung Cancer

Patients with NSCLC experienced improvements in both function and quality of life with yoga therapy.

Potential Delays in Non-Small Cell Lung Cancer Therapy

Potential Delays in Non-Small Cell Lung Cancer Therapy

Study results stress the importance of a multiethnic support system for patients needing to overcome communication barriers.

New "Pan-Can" Model More Accurately Predicts Lung Cancer Risk

New "Pan-Can" Model More Accurately Predicts Lung Cancer Risk

PanCan study effectively identified patients who eventually developed early-stage lung cancer, compared to other predictive models.

Updated Lung Cancer Screening Guidelines Released at CHEST

Updated Lung Cancer Screening Guidelines Released at CHEST

The ACCP just released new lung cancer screening guidelines.

Lung Cancer Screening Endorsed by Pulmonary and Primary Care Providers

Lung Cancer Screening Endorsed by Pulmonary and Primary Care Providers

Researchers surveyed knowledge, beliefs, attitudes, barriers, and facilitators related to screening patients for lung cancer.

Small-cell Lung Cancer Benefits From Maintenance Therapy With Pazopanib

Small-cell Lung Cancer Benefits From Maintenance Therapy With Pazopanib

Pazopanib improves progression-free survival in patients with small-cell lung cancer.

Gefitinib Treatment Should Be Avoided Prior to Chemotherapy in Non-small Cell Lung Cancer

Gefitinib Treatment Should Be Avoided Prior to Chemotherapy in Non-small Cell Lung Cancer

First generation EGFR tyrosine kinase inhibitors should be used in combination with chemotherapy if a patient has progressive EGFR mutation-positive non-small cell lung cancer.

Dacomitinib vs Gefitinib for Progression-Free Survival in Non-small Cell Lung Cancer

Dacomitinib vs Gefitinib for Progression-Free Survival in Non-small Cell Lung Cancer

Dacomitinib improved progression-free survival in patients with non-small cell lung cancer.

Case Report: Small Cell Lung Cancer Case With Tumor Lysis Syndrome

Case Report: Small Cell Lung Cancer Case With Tumor Lysis Syndrome

Tumor lysis syndrome can occur even in the absence of chemotherapy, and clinicians should remain suspicious when patients demonstrate laboratory abnormalities.

Greater Depth of Response to Therapy Improves Survival in Non-small Cell Lung Cancer

Greater Depth of Response to Therapy Improves Survival in Non-small Cell Lung Cancer

Overall and progression-free survival were improved with greater depth of response to therapy in non-small cell lung cancer.

Thoracic Radiotherapy Does Not Increase Risk for Immune-Related AEs in Lung Cancer

Thoracic Radiotherapy Does Not Increase Risk for Immune-Related AEs in Lung Cancer

Patients with metastatic lung cancer who receive both both immune checkpoint inhibitors and thoracic radiotherapy.do not have a greater risk for immune-related adverse events.

Non-small Cell Lung Cancer Survival Improved With Adoptive Cellular Immunotherapy

Non-small Cell Lung Cancer Survival Improved With Adoptive Cellular Immunotherapy

Adjuvant adoptive cellular immunotherapy plus chemotherapy improved survival in patients with resected non-small cell lung caner.

Non-small Cell Lung Cancer Staging Accuracy Tied to Nodal Examination

Non-small Cell Lung Cancer Staging Accuracy Tied to Nodal Examination

Thoroughness of nodal examination determines prognostic value of non-small cell lung cancer staging.

Non-small Cell Lung Cancer Metastasis at Diagnosis May Be Predicted by Genetic Mutations

Non-small Cell Lung Cancer Metastasis at Diagnosis May Be Predicted by Genetic Mutations

ROS1 and ALK rearrangements in patients with non-small cell lung cancer may predict different metastasis distributions at diagnosis.

Diagnostic Test Can Identify Biomarkers to Detect Lung Cancer

Diagnostic Test Can Identify Biomarkers to Detect Lung Cancer

A new diagnostic test and algorithm may be able to diagnose lung cancer from tumor-educated platelets.

Lung Cancer Is a Significant Cause of Death in Smokers Living With HIV

Lung Cancer Is a Significant Cause of Death in Smokers Living With HIV

Smokers with HIV who are adherent to antiretroviral therapy are still likely to die from lung cancer.

Standard vs High-Dose Chemoradiation in Stage 3 Non-Small Cell Lung Cancer

Standard vs High-Dose Chemoradiation in Stage 3 Non-Small Cell Lung Cancer

Higher doses of chemoradiation in stage 3 non-small cell lung cancer did not improve overall survival rates.

Impact of Canakinumab on Mortality, Incidence of Lung Cancer

Impact of Canakinumab on Mortality, Incidence of Lung Cancer

There may be a decreased rate of lung cancer for patients who receive anti-inflammatory therapy with canakinumab.

Durvalumab Linked to Longer Progression-Free Survival in NSCLC

Durvalumab Linked to Longer Progression-Free Survival in NSCLC

Fewer than 30% of patients undergoing durvalumab therapy experienced either grade 3 or 4 adverse events.

Does CT Scan at Follow-up Improve Resected NSCLC Survival?

Does CT Scan at Follow-up Improve Resected NSCLC Survival?

Recommendations to include CT scans as standard follow-up procedure is based on poor evidence.

FDA: Bevacizumab-awwb First Biosimilar Approved for Anticancer Therapy

FDA: Bevacizumab-awwb First Biosimilar Approved for Anticancer Therapy

Bevacizumab-awwb was approved based on pharmacokinetic and pharmacodynaic profiles and immunogenicity, safety, and efficacy data.

Does Targeted Inflammation Therapy Reduce Risk of CV Events, Lung Cancer?

Does Targeted Inflammation Therapy Reduce Risk of CV Events, Lung Cancer?

Canakinumab vs placebo showed promising results in preventing recurrent cardiovascular events and incidences of lung cancer.

Improving Anorexia-Cachexia in Non-small Cell Lung Cancer

Improving Anorexia-Cachexia in Non-small Cell Lung Cancer

Data from 5 phase 2/3 studies demonstrate improved weight and body mass in patients with NSCLC receiving anamorelin.

Improving Survival in Resected NSCLC With Adoptive Cellular Immunotherapy

Improving Survival in Resected NSCLC With Adoptive Cellular Immunotherapy

A phase 3 trial examined the efficacy of chemoimunnotherapy vs chemotherapy alone in postsurgical patients with non-small cell lung cancer.

Clinical Trial Eligibility Criteria: Barriers for People With Lung Cancer

Clinical Trial Eligibility Criteria: Barriers for People With Lung Cancer

A retrospective study of lung cancer clinical trials found that trials continue to increase their eligibility criteria, creating barriers to patient access.

FDA: Priority Review for Alectinib for ALK-positive NSCLC

FDA: Priority Review for Alectinib for ALK-positive NSCLC

Priority review for alectinib was granted based on evidence from the phase 3 ALEX and J-ALEX clinical trials.

FDA: Durvalumab Granted Breakthrough Therapy Designation for NSCLC

FDA: Durvalumab Granted Breakthrough Therapy Designation for NSCLC

Durvalumab can be used to treat patients with locally advanced, unrescetable NSCLC, who do not relapse after platinum-based chemoradiation.

Lung Cancer Screening CT Scans in High-Risk Smokers Increase Cessation Rates

Lung Cancer Screening CT Scans in High-Risk Smokers Increase Cessation Rates

Patients who underwent lung CT screening had a higher 2-week smoking cessation rate vs patients who did not undergo screening.

Pulmonary Rehabilitation Benefits in COPD, Lung Cancer, and Other Respiratory Conditions

Pulmonary Rehabilitation Benefits in COPD, Lung Cancer, and Other Respiratory Conditions

Recent research suggests that perioperative and postoperative pulmonary rehabilitation improves outcomes in patients undergoing thoracic surgery.

Alternative vs Usual Tx Outcomes for Lung, Breast, Colorectal Cancers

Alternative vs Usual Tx Outcomes for Lung, Breast, Colorectal Cancers

Patients who underwent alternative therapies were more likely to die vs those who underwent usual care.

B Vitamin Supplementation Not Associated With Decreased Cancer Risk

B Vitamin Supplementation Not Associated With Decreased Cancer Risk

Men and male smokers were most impacted by the association between vitamin B6 and B12 supplementation and lung cancer risk.

Accuracy of Physician Estimates of Pulmonary Nodule Pretest Probability of Malignancy

Accuracy of Physician Estimates of Pulmonary Nodule Pretest Probability of Malignancy

Physicians can differentiate between benign and malignant pulmonary nodules, but do not consistently follow guideline-based recommendations when selecting the next diagnostic test.

Does Palifosfamide With Platinum Doublet Prolong SCLC Survival?

Does Palifosfamide With Platinum Doublet Prolong SCLC Survival?

Palifosfamide added to carboplatin and etoposide did not prolong survival among patients with extensive-stage small-cell lung cancer.

Incident Lung Cancer Associated With Total, Saturated Fat Consumption

Incident Lung Cancer Associated With Total, Saturated Fat Consumption

Over 18,000 cases of incident lung cancer were identified over mean 9.4 years of follow-up.

ASCO Releases Updated Guidelines for Antiemetics in Cancer Patients

ASCO Releases Updated Guidelines for Antiemetics in Cancer Patients

ASCO has released updated guidelines to help physicians manage nausea and vomiting caused by antineoplastic agents in cancer patients.

Caregiver vs Patient View of Functional Status in Older Cancer Patients

Caregiver vs Patient View of Functional Status in Older Cancer Patients

Caregivers often rate patients as having poorer functional status than patients rate themselves.

Predicting Overall Survival With Neutrophil-Lymphocyte Ratio in NSCLC

Predicting Overall Survival With Neutrophil-Lymphocyte Ratio in NSCLC

Valuable information regarding patients' life expectancy can be collected through neutrophil-lymphocyte ratio biomarkers.

Child Intelligence Scores Tied to Mortality Risk for CV, Respiratory, Digestive Diseases

Child Intelligence Scores Tied to Mortality Risk for CV, Respiratory, Digestive Diseases

Childhood intelligence scores are associated with lower risk of mortality caused by coronary heart disease, cancers related to smoking, respiratory diseases, digestive diseases, injury, and dementia.

Efficacy of Neoadjuvant Nivolumab in NSCLC

Efficacy of Neoadjuvant Nivolumab in NSCLC

Researchers considered the response rate "encouraging" and comparable to cisplatin-based neoadjuvant therapy outcomes.

Examining the Relationship Between Neurocognitive Function and QoL in Advanced Lung Cancer

Examining the Relationship Between Neurocognitive Function and QoL in Advanced Lung Cancer

Patients with metastatic lung cancer require careful considerations concerning quality of life.

9/11 First Responders Experiencing Higher Rates of Chronic Cardiovascular, Respiratory Diseases

9/11 First Responders Experiencing Higher Rates of Chronic Cardiovascular, Respiratory Diseases

Intense exposure over the course of a single day has been linked to an elevated risk of developing chronic health conditions.

Efficacy of Once- vs Twice-daily Ratiotherapy for SCLC With Concurrent Chemoradiotherapy

Efficacy of Once- vs Twice-daily Ratiotherapy for SCLC With Concurrent Chemoradiotherapy

The randomzied, phase 3 CONVERT trial examined 547 patients with small-cell lung cancer.

Treating Limited-stage Small-cell Lung Cancer With Proton-beam Tx

Treating Limited-stage Small-cell Lung Cancer With Proton-beam Tx

Results showed that proton-beam therapy in small-cell lung cancer can be safe in combined modality therapy.

Survival Outcomes With Nivolumab vs Chemotherapy for Stage IV, Recurrent NSCLC

Survival Outcomes With Nivolumab vs Chemotherapy for Stage IV, Recurrent NSCLC

Findings in patients with previously untreated disease with PD-L1 expression level of 5%.

Improving NSCLC Outcomes With Midtreatment FDG-PET-Driven Radiation Tx

Improving NSCLC Outcomes With Midtreatment FDG-PET-Driven Radiation Tx

Increased radiation therapy based on midtreatment residual tumor FDG-PET may improve local control among patients with advanced NSCLC.

Pack-Year Smoking History Best Elicited by Shared-Decision Making

Pack-Year Smoking History Best Elicited by Shared-Decision Making

Electronic medical records inadequate for determining whether patients meet pack-year requirement for lung cancer screening researchers warn.

Survival Rate Increases With Adjuvant Gefitinib in NSCLC

Survival Rate Increases With Adjuvant Gefitinib in NSCLC

Adjuvant gefitnib increases disease-free survival for patients with stage II to III non-small lung cancer.

Glucose Dependency in Squamous Cell vs Adenocarcinoma NSCLC Tumors

Glucose Dependency in Squamous Cell vs Adenocarcinoma NSCLC Tumors

Data can be used to target the development of new drugs for treating squamous cell carcinomas.

ASTRO: New Guidelines for Stereotactic Body Radiation Therapy in NSCLC

ASTRO: New Guidelines for Stereotactic Body Radiation Therapy in NSCLC

ASTRO releases guidelines on stereotactic body radiation therapy for early-stage non-small cell lung cancer

Assessing Suicide Risk in Patients With Lung Cancer

Assessing Suicide Risk in Patients With Lung Cancer

Lung cancer diagnosis raised the odds of suicide by over four times in comparison to the general population according to a study presented at annual meeting of ATS.

Does Docetaxel Plus Selumetinib in NSCLC Increase Progression-Free Survival?

Does Docetaxel Plus Selumetinib in NSCLC Increase Progression-Free Survival?

The added combination of selumetinib with docetaxel did not improve progression-free survival among patients previously treated for advanced NSCLC.

Vaccine Therapies Show Promise As Lung Cancer Tx

Vaccine Therapies Show Promise As Lung Cancer Tx

Developed in Cuba, the TG4010 and CIMAvax-EGF vaccines are undergoing clinical study in the US.

Alectinib Safe and Effective for Non-Small Cell Lung Cancer

Alectinib Safe and Effective for Non-Small Cell Lung Cancer

Two new medications may improve survival for patients with specific types of advanced non-small-cell lung cancer.

Elevated Rates of Lung Adenocarcinoma Associated With Filtered Cigarettes

Elevated Rates of Lung Adenocarcinoma Associated With Filtered Cigarettes

A report published in the Journal of the National Cancer Institute suggests that the FDA should require cigarette filters to remove the holes.

Sequental Durvalumab Ups Progression-Free Survival in NSCLC

Sequental Durvalumab Ups Progression-Free Survival in NSCLC

Participants in the phase 3 PACIFIC trial randomly received sequential treatment with either durvalumab or placebo.

Alectinib Therapy Linked To Progression-Free Survival In ALK-Positive NSCLC

Alectinib Therapy Linked To Progression-Free Survival In ALK-Positive NSCLC

Alectinib, a selective ALK inhibitor, was found to have an objective response rate of 92% among patients with ALK-positive NSCLC.

FDA Approves For Combination Pembrolizumab Plus Pemetrexed/Carboplatin Therapy For NSCLC

FDA Approves For Combination Pembrolizumab Plus Pemetrexed/Carboplatin Therapy For NSCLC

Approval was based on tumor response rate and progression-free survival data, gathered from the KEYNOTE-021 study.

FDA Grants Accelerated Approval to Brigatinib for Metastatic NSCLC

FDA Grants Accelerated Approval to Brigatinib for Metastatic NSCLC

The Food and Drug Administration (FDA) has granted accelerated approval to Alunbrig (brigatinib; ARIAD) tablets.

Investigational Drug for NSCLC Granted Breakthrough Therapy Designation

Investigational Drug for NSCLC Granted Breakthrough Therapy Designation

FDA grants Pfizer's lorlatinib the Breakthrough Therapy designation for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer.

Thoracic Paravertebral Nerve Block to Treat Postthoracotomy Pain

Thoracic Paravertebral Nerve Block to Treat Postthoracotomy Pain

Continuous thoracic paravertebral nerve block, epidural anesthesia similarly effective for the management of postthoracotomy pain.

Reoccurrence and Mortality, NSCLC Linked to Chromosome Instability

Reoccurrence and Mortality, NSCLC Linked to Chromosome Instability

Chromosome instability was associated with an increased risk of recurrence and mortality among patients with early-stage non-small cell lung cancer.

NSCLC: Timing in EGFR mutation-related ctDNA Test Results

NSCLC: Timing in EGFR mutation-related ctDNA Test Results

Timing might affect the results of an EGFR mutation-frequency circulating tumor DNA test among patients with advanced non-small cell lung cancer.

PD-L1 Inhibitor Approved by FDA for Non-Small Cell Lung Cancer

PD-L1 Inhibitor Approved by FDA for Non-Small Cell Lung Cancer

Atezolizumab was approved for patients with non-small cell lung cancer.

Do Medicare Regulations Impact Lung Cancer Screening Rates?

Do Medicare Regulations Impact Lung Cancer Screening Rates?

Annual lung cancer screenings using low-dose computed tomography among high-risk individuals remain "low and unchanged."

Effect of Nivolumab on Long-term Survival in Lung Cancer

Effect of Nivolumab on Long-term Survival in Lung Cancer

Immune checkpoint inhibition with nivolumab is associated with durable clinical responses and a 16% 5-year survival rate among heavily pretreated patients with advanced non-small cell lung cancer.

FDA Approval: Osimertinib indication for EGFR T790M Mutation-positive NSCLC

FDA Approval: Osimertinib indication for EGFR T790M Mutation-positive NSCLC

The FDA approved osimertinib for treatment of EGFR T790M mutation positive non-small cell lung cancer.

Stereotactic Body Radiotherapy Safe and Effective for Elderly Patients NSCLC

Stereotactic Body Radiotherapy Safe and Effective for Elderly Patients NSCLC

Definitive lung stereotactic body radiotherapy in elderly patients with inoperable lung cancer is safe and effective.

Influence of Race in Management and Outcome of Stage I NSCLC

Influence of Race in Management and Outcome of Stage I NSCLC

Research from the National Cancer Institute found persistent racial disparities in treatment and outcomes among patients with non-small cell lung cancer.

Sign Up for Free e-newsletters